BANB: Future Earnings Execution Is Expected To Support CHF 80 Upside Potential

Analysts have nudged their price target on Bachem Holding slightly higher, with recent Street research indicating a CHF 5 increase from both Barclays and Deutsche Bank to CHF 80, supported by updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E.

Analyst Commentary

Bullish Takeaways

Bullish analysts see the move to a CHF 80 target as aligned with their updated view on fair value, suggesting that current assumptions on growth and margins justify a higher valuation anchor.
The consistent CHF 5 upward shift in targets points to confidence that Bachem can support a higher future P/E based on its business profile and earnings potential, even without specifying exact figures.
Revisions to discount rate and revenue growth inputs in recent models indicate that bullish analysts are comfortable with the risk profile they assign to Bachem at this level.
The clustering of targets around CHF 80 gives investors a clearer reference point for how the Street is framing upside versus execution risk in the current setup.

Bearish Takeaways

Even with the uplift to CHF 80, there is limited spread between the old and new targets, which may signal that analysts see only incremental changes in the risk or growth outlook rather than a major reset.
Higher fair value assumptions typically rely on models that are sensitive to inputs like revenue growth and profit margin, so any shortfall in execution could put pressure on the current P/E expectations.
The reliance on a specific target level such as CHF 80 highlights that valuation support is model based, and investors may want to consider how those models might react to changes in discount rates or earnings quality.
With targets now clustered at the same level, there is less differentiation in Street views, which can limit the range of independent scenarios investors see on both upside and downside cases.

What's in the News

Bachem Holding plans an Analyst/Investor Day, which will give you a chance to hear management provide an update on the business and answer questions directly (Key Developments).
The company announced an annual dividend of CHF 0.4500 per share, with ex date on May 04, 2026, record date on May 05, 2026, and payment on May 06, 2026 (Key Developments).

Valuation Changes

Fair Value increased from CHF 78.3 to CHF 78.8, a small upward adjustment in the valuation anchor used in recent models.
The Discount Rate moved from 4.70% to 4.68%, a slight change that indicates a marginally different view of risk in the cash flow assumptions.
Revenue Growth was revised from 24.76% to 24.68%, a very small change that keeps growth expectations broadly in the same range.
Net Profit Margin increased from 18.87% to 18.93%, a minor uplift in expected profitability in the updated assumptions.
Future P/E moved from 26.47x to 26.58x, a modest change in the multiple applied to forward earnings estimates.

8 views

Key Takeaways

Significant expansion in large-scale manufacturing and process automation positions Bachem for outsized growth and improved margins amid rising demand for peptide and oligonucleotide drugs.
Strong long-term customer partnerships and leadership in advanced therapeutics offer recurring, less volatile revenue and structural advantage as biopharma outsourcing intensifies.
Large investment needs, currency risk, industry price pressures, and reliance on timely capacity expansion threaten Bachem's financial flexibility, margins, and future growth prospects.

Catalysts

About Bachem Holding

Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.What are the underlying business or industry changes driving this perspective?

Bachem's substantial investment in expanding large-scale manufacturing capacity-particularly with the new Building K expected to enter GMP production in 2025 and begin significant revenue contribution in 2026-positions the company to capture accelerating demand from high-growth peptide and oligonucleotide drug markets, supporting outsized future revenue growth.
The rapidly expanding pipeline of peptide and oligonucleotide therapeutics across multiple indications, including the massive projected growth in the anti-obesity market, provides strong, multi-year visibility for outsourcing demand; Bachem's leadership in these modalities and the current supply-demand imbalance offer the potential for sustained volume and pricing power, boosting both revenue and margins.
Continuous operational excellence initiatives, such as harmonization of processes across sites, implementation of shift work, network production, and increasing automation, are already delivering material cost efficiencies; these trends should drive further improvement in net margins and earnings as new capacity ramps.
The expansion of long-term customer partnerships-underscored by high visibility of prepayments from major pharma clients-aligns Bachem for recurring business, reduced revenue volatility, and consistent margin expansion as global biopharma intensifies outsourcing of complex molecule production.
Early, proactive investment in next-generation oligonucleotide manufacturing, with a healthy backlog of projects and clear order visibility, positions Bachem to benefit disproportionately as regulatory approvals increase and the global acceptance of these advanced therapeutics widens the addressable market, underpinning structural top-line growth.

Bachem Holding Earnings and Revenue Growth

Bachem Holding Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Bachem Holding's revenue will grow by 24.7% annually over the next 3 years.
Analysts assume that profit margins will shrink from 21.4% today to 18.9% in 3 years time.
Analysts expect earnings to reach CHF 255.1 million (and earnings per share of CHF 3.49) by about May 2029, up from CHF 148.8 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting CHF316.9 million in earnings, and the most bearish expecting CHF216.5 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 26.7x on those 2029 earnings, down from 35.7x today. This future PE is lower than the current PE for the GB Life Sciences industry at 34.3x.
Analysts expect the number of shares outstanding to grow by 0.21% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 4.68%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Significant ongoing and future CapEx requirements (including CHF 400+ million in 2025 and continued large-scale investments at multiple sites) could put sustained pressure on free cash flow and increase reliance on external debt financing, raising the risk of reduced financial flexibility and potentially dilutive equity needs if internal cash generation lags.
Heightened exposure to currency volatility, especially due to the strong Swiss franc and much of Bachem's revenue base in US dollars, is already impacting margins and net income (CHF 11 million FX loss in H1), and could weigh on future revenues and profitability if unfavorable exchange rate trends persist.
Intensifying industry-wide efficiency improvements and automation (both by Bachem and its competitors) could lead to pricing pressure on long-term customer contracts, reducing gross margins if cost savings are passed on to customers or if customers demand lower prices as the industry becomes more commoditized.
Heavy dependence on successful completion, regulatory approval, and commissioning of new manufacturing capacity (notably Building K and major US expansions) means that any delays, cost overruns, or regulatory setbacks could limit growth, lead to underutilization of assets, and pressure future earnings.
Persistent and rising operational and financing costs-including ramp-up costs for new facilities, increased personnel to support growth, and growing debt service-could erode net margins, especially if revenue growth slows, industry pricing pressure intensifies, or macroeconomic/FX headwinds worsen.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of CHF78.8 for Bachem Holding based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of CHF110.0, and the most bearish reporting a price target of just CHF46.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be CHF1.3 billion, earnings will come to CHF255.1 million, and it would be trading on a PE ratio of 26.7x, assuming you use a discount rate of 4.7%.
Given the current share price of CHF70.8, the analyst price target of CHF78.8 is 10.2% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Bachem Holding?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Building K Production Will Serve Peptide And Oligonucleotide Therapies